stockrow
Saturday 7 November 2026
Export ALMS’s income statement to Excel — free account
Alumis Inc.
ALMS Healthcare Biotechnology
Alumis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.1 million.
- Revenue
- −37.7%
- EPS
- −242.3%
- Free cash flow
- +23.6%
Quarter to June 2026, against a year earlier
6.02
0.17
+2.91%
Follow ALMS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (93.65%) | (64.57%) | (86.68%) | (66.88%) |
+8 more TTM periods Free account |
|
| (74.94%) | (50.90%) | (64.63%) | (54.44%) | ||
ROIC |
0.00% | (640.29%) | 0.00% | (4,042.96%) | |
Return on Tangible Assets |
(96.54%) | (49.56%) | (92.48%) | (70.66%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(2.76) | (3.01) | (4.35) | (3.59) | |
Free Cash Flow |
(351.80) | (377.03) | (370.18) | (373.40) | |
Capital Expenditures |
(0.40) | (0.78) | (0.65) | (1.02) | |
| Other line items | |||||
Cash ROIC |
(36.86%) | (34.59%) | (60.70%) | (48.97%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4,697.19% | 4,414.62% | 1,604.98% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,041.86% | 1,049.40% | 381.94% | 0.00% | |
Share Based Compensation of Revenue |
601.60% | 581.62% | 180.97% | 0.00% | |
Operating CF/Net income |
0.80 | 1.58 | 1.52 | 1.52 | |
Depreciation/Fixed assets |
2.69 | 0.20 | 0.19 | 0.18 | |
Capex/Depreciation |
(0.01) | (0.22) | (0.19) | (0.30) | |
Revenue per Share |
0.06 | 0.07 | 0.28 | 0.00 | |
Operating CF per Share |
(2.75) | (3.01) | (4.35) | (3.58) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.05 | 0.09 | 0.03 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026